Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000019.xml
Download PDF
Fortschr Neurol Psychiatr 2020; 88(02): 71-73
DOI: 10.1055/a-1075-3240
DOI: 10.1055/a-1075-3240
Fokussiert
Myostatin-Blockade mit Bimagrumab zeigt nicht den gewünschten Effekt bei sporadischer Einschlusskörpermyositis (s-IBM)
Authors
Zeigt Bimagrumab, ein monoklonaler Antikörper und Myostatin-Inhibitor, bei Patienten mit sporadischer Einschlusskörpermyositis (sIBM) Wirksamkeit hinsichtlich einer Verbesserung von Muskelkraft und Ausdauer?
Publication History
Article published online:
26 February 2020
© Georg Thieme Verlag KG
Stuttgart · New York
-
Literatur
- 1 Walter MC, Lochmüller H, Schlotter B, Reilich R, Müller-Felber W, Pongratz D. Neue Gesichtspunkte zur Pathogenese und Therapie der sporadischen Einschlusskörpermyositis (s-IBM). Nervenarzt 2001; 72: 117-121 .
- 2 Walter MC, Lochmüller H, Toepfer M, Schlotter B, Reilich P, Schröder M, Müller-Felber W, Pongratz D. High-dose immunoglobulin therapy (IVIG) in inclusion body myositis (IBM): A double-blind, placebo-controlled study. J Neurol 2000; 247: 22-28.
- 3 Wiendl H, Dengler R, Dörner T, Hohlfeld R, Melms A, Melzer N, Nast A, Rösler K, Schmidt J, Sinnreich M, Sunderkötter C, Walter MC, Wanschitz J, Worm M. DGN Leitlinien Myositissyndrome. https://www.dgn.org/leitlinien/3011-ll-69-ll-myositissyndrome . Vollständig überarbeitet September 2014
- 4 Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord; 2010. 20: 142-47.
- 5 Dalakas MC, Sonies B, Dambrosia J. et al. Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study. Neurology 1997; 48: 712-716
- 6 Dobloug C, Walle-Hansen R, Gran J. T. et al. (2012) Clin.Exp.Rheumatol. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients.
- 7 Recher M, Sahrbacher U, Bremer J. et al. 2012; Rheumatol.Int. 32: 469-472. Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?
- 8 Benveniste O, Guiguet M, Freebody J. et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134: 3176-84.
- 9 Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011; 134: 3167-75.
- 10 Polkey MI, Praestgaard J, Berwick A, Franssen FME, Singh D, Steiner MC, Casaburi R, Tillmann HC, Lach-Trifilieff E, Roubenoff R, Rooks DS.
- 11 Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial. Am J Respir Crit Care Med 2019; 199: 313-320 .
- 12 Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve 2017; 55: 458-464.
- 13 Mariot V, Joubert R, Hourdé C, Féasson L, Hanna M, Muntoni F, Maisonobe T, Servais L, Bogni C, Le Panse R, Benvensite O, Stojkovic T, Machado PM, Voit T, Buj-Bello A, Dumonceaux J. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun 2017; 8: 1859.